---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017354"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:36:25.165449+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A

## Summary
- Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
- Study evaluating safety, tolerability, antiviral and clinical measurements of CC-42344 for pandemic and seasonal influenza A.
- Topline results expected later this year; study conducted in the United Kingdom.
- Company also plans to begin Phase 1 study in Australia with inhaled formulation of CC-42344.
- Received positive Pre-IND feedback from FDA in March 2024 guiding Phase 2b protocol.

## SEC filing metadata
- accession: 0001493152-24-017354
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/0001493152-24-017354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017354
- JSON: https://secwatch.observer/filing/0001493152-24-017354.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.